Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
Rhea-AI Summary
Taysha Gene Therapies (Nasdaq: TSHA) reported full‑year 2025 results and a corporate update on March 19, 2026. Key program milestones include multiple patients dosed in the REVEAL pivotal trial, FDA clearance to initiate the ASPIRE trial, written FDA alignment on CMC/PPQ comparability, and no treatment‑related SAEs or DLTs as of March 2026.
Financials: R&D $86.4M, G&A $33.9M, net loss $109.0M, and $319.8M cash, with runway expected into 2028.
Positive
- FDA written alignment on CMC comparability and PPQ strategy
- FDA clearance to initiate ASPIRE trial in 2 to <4-year-olds
- Multiple patients dosed in REVEAL pivotal trial; dosing on track
- No treatment-related SAEs or DLTs reported as of March 2026
- Cash balance of $319.8M; expected runway into 2028
Negative
- Research and development expense increased to $86.4M (+$20.4M YoY)
- General and administrative expense increased to $33.9M (+$4.9M YoY)
- Net loss widened to $109.0M for full-year 2025
News Market Reaction – TSHA
On the day this news was published, TSHA gained 2.47%, reflecting a moderate positive market reaction. Argus tracked a peak move of +3.0% during that session. Argus tracked a trough of -7.4% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $30M to the company's valuation, bringing the market cap to $1.25B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TSHA fell 2.63% while momentum scans flagged only one peer (IOVA) moving up. Other high-affinity peers like QURE, SANA, EYPT and UPB also showed single-day declines, but scanner data does not confirm a coordinated sector move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 04 | Q3 2025 earnings | Positive | -4.3% | Reported Q3 2025 results and TSHA-102 Breakthrough Therapy designation. |
| Aug 12 | Q2 2025 earnings | Positive | +5.4% | Q2 2025 results with strong TSHA-102 data and $230M offering cash boost. |
| May 15 | Q1 2025 earnings | Positive | +8.0% | Q1 2025 update featuring FDA alignment on pivotal design and safety data. |
| Feb 26 | FY 2024 earnings | Positive | -4.7% | Full-year 2024 results with REVEAL dosing progress and higher R&D spend. |
| Nov 13 | Q3 2024 earnings | Positive | +2.7% | Q3 2024 update on TSHA-102 safety, FDA manufacturing endorsement, and cash. |
Earnings updates with positive TSHA-102 progress have often led to upside, but there are instances where shares declined despite favorable regulatory or clinical milestones.
Over the last five earnings cycles, Taysha repeatedly highlighted progress for TSHA-102 in Rett syndrome, including FDA Breakthrough Therapy designation, pivotal trial alignment, and consistently favorable safety data with no treatment-related SAEs or DLTs. Financially, cash positions ranged from $116.6M to $312.8M, with runway often guided into 2028. Some earnings reports, such as Nov 4, 2025 and Feb 26, 2025, saw share price declines despite constructive updates, indicating that positive operational news has not always translated into immediate price strength.
Historical Comparison
Across the last 5 earnings updates, TSHA moved an average of ±1.44%. Today’s -2.63% reaction sits modestly outside that norm but not as a major outlier.
Earnings updates have tracked TSHA-102’s path from early REVEAL safety data and FDA alignment, through Breakthrough Therapy designation, to pivotal REVEAL enrollment and a BLA-enabling strategy.
Market Pulse Summary
This announcement combines pivotal clinical progress for TSHA-102 with a detailed full-year 2025 financial update. Key points include dosing advancement in the REVEAL and ASPIRE trials, maintained tolerability with no treatment-related SAEs or DLTs, and cash of $319.8M expected to fund operations into 2028. Rising R&D to $86.4M and net loss of $109.0M highlight ongoing investment needs. Future updates on REVEAL data, BLA timing, and spending trends will be important to monitor.
Key Terms
Biologics License Application (BLA) regulatory
intrathecal medical
serious adverse events (SAEs) medical
dose-limiting toxicities (DLTs) medical
Chemistry Manufacturing and Controls (CMC) regulatory
Process Performance Qualification (PPQ) technical
at-the-market equity offering program financial
AI-generated analysis. Not financial advice.
Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026
Received FDA clearance to initiate ASPIRE trial in three patients aged 2 to <4 years with inclusion of ≥3 months of safety data in planned BLA submission to support potential for broad label; on track to complete dosing in Q2 2026
Maintained favorable tolerability profile with no treatment-related SAEs or DLTs in REVEAL Phase 1/2 and REVEAL pivotal trials as of March 2026 data cutoff; longer-term safety and efficacy data from Part A of REVEAL Phase 1/2 trials expected in Q2 2026
Reached written alignment with FDA on proposed PPQ and comparability strategy for commercial TSHA-102 manufacturing to support planned BLA submission package
Conference call and webcast today at 8:30 AM ET
DALLAS, March 19, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the full year ended December 31, 2025, and provided a corporate update.
“2025 was a year of significant execution for Taysha, setting the stage for what we expect to be a transformative year ahead. We are focused on completing the pivotal development of TSHA-102 and bolstering our commercial readiness efforts as we advance toward potential registration. Multiple patients have been dosed in our REVEAL pivotal trial, and we remain on track to complete dosing in the REVEAL pivotal and ASPIRE trials in the second quarter of this year,” said Sean P. Nolan, Chairman and Chief Executive Officer of Taysha.
Mr. Nolan continued, “Importantly, we have maintained ongoing, constructive dialogue with the FDA over the past two years that continues to support a streamlined path to registration. We recently received written FDA alignment on our proposed PPQ and comparability strategy, including the ability to leverage data across the REVEAL and ASPIRE trials to support our planned BLA submission. In parallel, recent market research reinforces the strong commercial opportunity for TSHA-102, demonstrating high anticipated demand from both clinicians and caregivers in the U.S. The research also indicates a clear preference for intrathecal administration, which is viewed as familiar, accessible and scalable, enabling the potential to safely and efficiently treat patients across multiple institutions. With a favorable tolerability profile demonstrated to date, continued patient enrollment and a well defined regulatory and commercial path, we believe TSHA 102 has the potential to meaningfully address the genetic root cause of this devastating disease with high unmet need.”
Recent Corporate and TSHA-102 Program Highlights
- Dosed Multiple Patients in REVEAL Pivotal Trial with Additional Enrollment Advancing Across Multiple Clinical Trial Sites. The single-arm, open-label trial is evaluating a single intrathecal (IT) administration of high dose TSHA-102 (1x1015 total vector genomes (vg)) in 15 females between the ages of 6 and <22 years in the developmental plateau population of Rett syndrome. The primary endpoint will assess response rate, defined as the percentage of patients who gain or regain ≥one of the 28 natural history-defined developmental milestones, with each patient serving as their own control. The study includes a six-month interim analysis that may serve as the basis for Biologics License Application (BLA) submission.
- Received FDA Clearance to Initiate the ASPIRE Trial and Written Alignment on Data for Inclusion in BLA Submission to Enable Broad Label. In January 2026, Taysha announced written alignment with the U.S. Food and Drug Administration (FDA) on the ASPIRE safety-focused trial and the data for inclusion in the planned BLA submission to enable broad labeling of TSHA-102 for patients aged ≥2 years with Rett syndrome. Subsequently, the Company received FDA clearance to initiate the ASPIRE trial. Taysha is enrolling three females with Rett syndrome, aged 2 to <4 years, to evaluate the safety and preliminary efficacy of a single IT administration of high dose TSHA-102 (1x1015 total vg), scaled to account for the lower brain volume in 2 to <4-year-olds.
- A minimum of three months of ASPIRE safety data will be included in the planned BLA submission, while efficacy in the 2 to <6-year-old population will be extrapolated from data collected in the REVEAL pivotal trial.
- TSHA-102 Continues to be Generally Well Tolerated. High dose (1x1015 total vg) and low dose (5.7x1014 total vg) TSHA-102 continue to be generally well tolerated with no treatment-related serious adverse events (SAEs) or dose-limiting toxicities (DLTs) in the patients treated in the REVEAL Phase 1/2 trials and the REVEAL pivotal trial as of the March 2026 data cutoff.
- Reached Written FDA Alignment on CMC Requirements for TSHA-102 Supporting Planned BLA Submission Package. Following a Type C Meeting with the FDA in the first quarter of 2026, Taysha further aligned on the following Chemistry Manufacturing and Controls (CMC) requirements to support the planned BLA submission in parallel with its clinical development timelines:
- Alignment on the proposed comparability approach between TSHA-102 material derived from the clinical and final commercial manufacturing processes. The FDA agreed that the approach may support pooling data from the REVEAL Phase 1/2 trials with data from the ongoing REVEAL pivotal and ASPIRE trials for the planned BLA submission.
- Endorsement of the Company’s proposed Process Performance Qualification (PPQ) campaign strategy to support process validation for the BLA submission, including:
- Stability data package
- Potency assay strategy
- Execution of BLA-enabling PPQ lots using the commercial manufacturing process, with initiation expected in Q2 2026
- Advanced Commercial Readiness Activities:
- Further strengthened commercial leadership team with the appointment of Brad Martin as Senior Vice President, Market Access and Value in February 2026. Mr. Martin brings over two decades of market access and commercial strategy experience in gene therapy, having held senior roles at Neurotech Pharmaceuticals, Sarepta Therapeutics and AveXis. At AveXis, he played a crucial role in securing market access for the blockbuster gene therapy Zolgensma for the treatment of spinal muscular atrophy.
- Completed market research demonstrating strong clinician and caregiver demand and anticipated broad adoption of TSHA-102 for the 6,000 to 9,000 pediatric, adolescent and adult patients with Rett syndrome in the U.S., with a clear preference for intrathecal administration, reinforcing the significant commercial potential of TSHA-102.
Anticipated Milestones
- Completion of dosing in the REVEAL pivotal trial is expected in the second quarter of 2026
- Completion of dosing in the ASPIRE trial is expected in the second quarter of 2026
- Update on longer-term safety and efficacy data from Part A of REVEAL Phase 1/2 trials expected in the second quarter of 2026
Full-Year 2025 Financial Highlights
Research and Development Expenses: Research and development expenses were
General and Administrative Expenses: General and administrative expenses were
Net Loss: Net loss for the year ended December 31, 2025, was
Cash and Cash Equivalents: As of December 31, 2025, Taysha had
Conference Call and Webcast Information
Taysha management will host a live conference call and webcast today at 8:30 a.m. ET to review its financial and operating results and provide a corporate update. Participants may access the live webcast of the conference call by visiting Taysha’s website.
About TSHA-102
TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome. Designed as a one-time treatment, TSHA-102 aims to address the genetic root cause of the disease by delivering a functional form of MECP2 to cells in the CNS. TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression. TSHA-102 has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Fast Track and Orphan Drug and Rare Pediatric Disease designations from the FDA, Orphan Drug designation from the European Commission and Innovative Licensing and Access Pathway designation from the Medicines and Healthcare products Regulatory Agency.
About Rett Syndrome
Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene encoding methyl CpG-binding protein 2 (MeCP2), which is essential for regulating neuronal and synaptic function in the brain. The disorder is characterized by loss of communication and hand function, slowing and/or regression of development, motor and respiratory impairment, seizures, intellectual disabilities and shortened life expectancy. Rett syndrome progression is divided into four key stages, beginning with early onset stagnation at 6 to 18 months of age followed by rapid regression, plateau and late motor deterioration. Rett syndrome primarily occurs in females and is one of the most common genetic causes of severe intellectual disability. Currently, there are no approved disease-modifying therapies that treat the genetic root cause of the disease. Rett syndrome caused by a pathogenic/likely pathogenic MECP2 mutation is estimated to affect between 15,000 and 20,000 patients in the U.S., EU, and U.K.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include, but are not limited to, statements concerning the potential of TSHA-102 and Taysha’s other product candidates to positively impact quality of life and alter the course of disease in the patients Taysha seeks to treat, Taysha’s research, development and regulatory plans for its product candidates, communications with the FDA, including with respect to the BLA for TSHA-102, the potential for Taysha’s product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and whether, if approved, these product candidates will be successfully distributed and marketed and the potential market opportunity for Taysha’s product candidates, including anticipated clinician and caregiver demand. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Taysha’s business are described in detail in Taysha’s Securities and Exchange Commission (“SEC”) filings, including in our Annual Report on Form 10-K for the full-year ended December 31, 2025, which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that Taysha makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Taysha disclaims any obligation to update these statements except as may be required by law.
| Taysha Gene Therapies, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) | ||||||||
| For the Year Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Revenue | $ | 9,773 | $ | 8,333 | ||||
| Operating expenses: | ||||||||
| Research and development | 86,403 | 66,001 | ||||||
| General and administrative | 33,868 | 28,953 | ||||||
| Impairment of long-lived assets | — | 4,838 | ||||||
| Total operating expenses | 120,271 | 99,792 | ||||||
| Loss from operations | (110,498 | ) | (91,459 | ) | ||||
| Other income (expense): | ||||||||
| Change in fair value of warrant liability | (1,199 | ) | 16 | |||||
| Change in fair value of term loan | (6,168 | ) | (4,583 | ) | ||||
| Interest income | 9,224 | 6,940 | ||||||
| Interest expense | (63 | ) | (102 | ) | ||||
| Other expense | (291 | ) | (110 | ) | ||||
| Total other income, net | 1,503 | 2,161 | ||||||
| Net loss | $ | (108,995 | ) | $ | (89,298 | ) | ||
| Net loss per common share, basic and diluted | $ | (0.34 | ) | $ | (0.36 | ) | ||
| Weighted average common shares outstanding, basic and diluted | 319,711,972 | 250,134,421 | ||||||
| Taysha Gene Therapies, Inc. Condensed Consolidated Balance Sheet Data (in thousands, except share and per share data) | ||||||||
| December 31, 2025 | December 31, 2024 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 319,767 | $ | 139,036 | ||||
| Restricted cash | 449 | 449 | ||||||
| Prepaid expenses and other current assets | 4,431 | 2,645 | ||||||
| Total current assets | 324,647 | 142,130 | ||||||
| Restricted cash | 2,315 | 2,151 | ||||||
| Property, plant and equipment, net | 6,736 | 7,485 | ||||||
| Operating lease right-of-use assets | 9,439 | 8,381 | ||||||
| Other non-current assets | 183 | 217 | ||||||
| Total assets | $ | 343,320 | $ | 160,364 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 6,275 | $ | 3,592 | ||||
| Accrued expenses and other current liabilities | 20,277 | 12,862 | ||||||
| Deferred revenue | — | 9,773 | ||||||
| Total current liabilities | 26,552 | 26,227 | ||||||
| Term loan, net | 50,106 | 43,942 | ||||||
| Operating lease liability, net of current portion | 18,172 | 17,361 | ||||||
| Other non-current liabilities | 1,552 | 1,309 | ||||||
| Total liabilities | 96,382 | 88,839 | ||||||
| Stockholders' equity | ||||||||
| Preferred stock, | — | — | ||||||
| Common stock, | 3 | 2 | ||||||
| Additional paid-in capital | 958,427 | 677,859 | ||||||
| Accumulated other comprehensive loss | (192 | ) | (4,031 | ) | ||||
| Accumulated deficit | (711,300 | ) | (602,305 | ) | ||||
| Total stockholders’ equity | 246,938 | 71,525 | ||||||
| Total liabilities and stockholders' equity | $ | 343,320 | $ | 160,364 | ||||
Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com
FAQ
What is Taysha's timeline to complete dosing in REVEAL and ASPIRE (TSHA)?
Has the FDA provided alignment for TSHA-102 commercial manufacturing and BLA submission (TSHA)?
What safety profile has Taysha reported for TSHA-102 as of March 2026 (TSHA)?
How strong is Taysha's cash position and runway after 2025 results (TSHA)?
What were Taysha's key 2025 financial changes that investors should note (TSHA)?
Will ASPIRE safety data be included in Taysha's planned BLA submission for TSHA-102 (TSHA)?
